3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Endocrine
1
CNS
1
Breast
1
Conditions
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Interventions
Carboplatin
542
Pemetrexed
392
pembrolizumab
372
Cisplatin
356
Paclitaxel
285
Docetaxel
240
Gemcitabine
168
Nivolumab
158
Erlotinib Hydrochloride
147
Bevacizumab
114
atezolizumab
104
osimertinib
99
durvalumab
92
Etoposide
90
Gefitinib
68
130-nm albumin-bound paclitaxel
65
Cetuximab
64
Ipilimumab
60
Drug Therapy
51
Topotecan
48
Injections
44
Afatinib
41
tislelizumab
40
Cyclophosphamide
39
Albumin-Bound Paclitaxel
37
Vinorelbine
36
Crizotinib
34
cemiplimab
31
icotinib
26
Radiotherapy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biological Therapy
×
Thoracic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled